Acasti Pharma Statistics
Total Valuation
Acasti Pharma has a market cap or net worth of $25.94 million. The enterprise value is $7.52 million.
| Market Cap | 25.94M |
| Enterprise Value | 7.52M |
Important Dates
The next estimated earnings date is Friday, June 21, 2024, before market open.
| Earnings Date | Jun 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Acasti Pharma has 9.40 million shares outstanding.
| Shares Outstanding | 9.40M |
| Owned by Insiders (%) | 16.02% |
| Owned by Institutions (%) | 12.17% |
| Float | 6.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.55 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.19, with a Debt / Equity ratio of 0.00.
| Current Ratio | 15.19 |
| Quick Ratio | 14.73 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 154.76 |
Financial Efficiency
Return on equity (ROE) is -58.90% and return on invested capital (ROIC) is -73.66%.
| Return on Equity (ROE) | -58.90% |
| Return on Assets (ROA) | -50.60% |
| Return on Capital (ROIC) | -73.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -7.21M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.68% in the last 52 weeks. The beta is 1.56, so Acasti Pharma's price volatility has been higher than the market average.
| Beta (1Y) | 1.56 |
| 52-Week Price Change | -10.68% |
| 50-Day Moving Average | 3.17 |
| 200-Day Moving Average | 2.63 |
| Relative Strength Index (RSI) | 38.85 |
| Average Volume (30 Days) | 23,578 |
Short Selling Information
| Short Interest | 1,135 |
| Short Previous Month | 3,819 |
| Short % of Shares Out | 0.01% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.00M |
| Pretax Income | -35.68M |
| Net Income | -38.77M |
| EBITDA | -35.90M |
| EBIT | -35.91M |
| Earnings Per Share (EPS) | -$3.73 |
Balance Sheet
The company has $18.44 million in cash and $17,624 in debt, giving a net cash position of $18.42 million or $1.96 per share.
| Cash & Cash Equivalents | 18.44M |
| Total Debt | 17,624 |
| Net Cash | 18.42M |
| Net Cash Per Share | $1.96 |
| Equity / Book Value | 47.50M |
| Book Value Per Share | 5.05 |
| Working Capital | 18.44M |
Cash Flow
In the last 12 months, operating cash flow was -$9.97 million and capital expenditures $74,901, giving a free cash flow of -$9.89 million.
| Operating Cash Flow | -9.97M |
| Capital Expenditures | 74,901 |
| Free Cash Flow | -9.89M |
| FCF Per Share | -$0.86 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Acasti Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -54.75% |
| Shareholder Yield | -54.75% |
| Earnings Yield | -149.47% |
| FCF Yield | -38.13% |
Analyst Forecast
The average price target for Acasti Pharma is $6.00, which is 117.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 117.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 10, 2023. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jul 10, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |